Will gilteritinib be included in medical insurance in 2023? What is the price after medical insurance?

gilteritinib is a kinase inhibitor that inhibits FLT3-ITD and F The activity of LT3-TKD blocks cell division and proliferation, thereby treating uncontrolled, slowly progressive or refractory acute myeloid leukemia (AML).

Gilteritinib(gilteritinib) is produced by JapanAstellas Pharma, Inc. .The anti-tumor drug developed and released on2018year9month21dayGiritinib (XOSPATA) Obtained marketing approval in Japan,2018Year11Month28Nikkei America FDAapproved for marketing, and was approved for marketing by China Food and Drug Administration on January 31 of 2021. However, it has not yet been included in medical insurance and cannot be reimbursed. The current domestic retail price is 40mg*21tablets*2board258,000yuan. There are also generic versions of giritinib, and the currently officially marketed version is the Lao version. The retail price of 40mg 90 tablets is around 4000 yuan.

Before initiating AMLtreatment, confirm the presence of Flt-3 mutations(peripheral blood or bone marrow). Before starting treatment, monitor complete blood counts and blood chemistries, including CK, at least weekly for the first month of treatment, every other week for the next month, and monthly thereafter. Before the start of treatment, on day 1 of cycle 8 and day 15 and on day 2An electrocardiogram is performed before the start of the and 3 cycles. Giritinib is taken orally once daily, with or without food, at approximately the same time each day. Swallow the tablets with water without chewing, crushing or breaking them. If you want to get more high-quality information, you can contact YaoDe. YaoDe will do its best to learn more about high-quality overseas drugs for you.